DiaGenic is an innovative Norwegian biotechnology company that seeks
to create value for patients, partners, and investors by developing
new and more patient-friendly methods for early detection of
DiaGenic is currently a world leader in analyzing gene expression
signatures related to disease in easily available clinical samples
such as peripheral blood. This unique method is based on the
principle that even when a disease is localized at a specific part
of the body, secondary responses, which are also characteristic of
the disease, can be measured in other parts.
Significant potential in numerous diseases such as breast cancer and
Alzheimer's disease has been identified. The company has been
granted patents in the U.S. and Europe. DiaGenic is listed on the
Oslo Stock Exchange.